Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
19. September 2022 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September...
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
19. Mai 2022 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
20. Januar 2022 08:45 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its...
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
22. November 2021 10:00 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
15. Oktober 2021 10:21 ET
|
Adhera Therapeutics, Inc.
IP Estate Grows with New Korean Patent Issued Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
04. Oktober 2021 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
13. September 2021 10:28 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...